A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer.
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and
immunogenicity of MRG003 in patients with EGFR-positive, HER2-negative, inoperable locally
advanced or metastatic gastric cancer.